Fresenius Medical Care ( (FMS) ) has shared an update.
On February 25, 2025, Fresenius Medical Care announced the filing of its annual report for the fiscal year 2024 on Form 20-F with the U.S. Securities and Exchange Commission. This report, which includes the complete audited consolidated financial statements, is accessible on both the company’s and the SEC’s websites. This filing is a significant step in maintaining transparency and regulatory compliance, offering stakeholders a detailed view of the company’s financial health and operational performance over the past year.
More about Fresenius Medical Care
Fresenius Medical Care is the world’s leading provider of products and services for individuals with renal diseases, serving approximately 4.2 million patients globally who regularly undergo dialysis treatment. The company operates a network of 3,675 dialysis clinics, providing treatments for around 299,000 patients worldwide, and is a leading supplier of dialysis products such as machines and dialyzers. Fresenius Medical Care is publicly traded on the Frankfurt Stock Exchange and the New York Stock Exchange.
YTD Price Performance: 5.24%
Average Trading Volume: 253,501
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $13.7B
See more insights into FMS stock on TipRanks’ Stock Analysis page.